BioSpace News Archive

The rising incidence of infectious diseases worldwide, coupled with the growing demand for protein therapeutics, is supporting the progress of the global antibody production market.

Inflammasome Therapeutics reported that data analyses published in Nature Communications https://www.nature.com/articles/s41467-020-18528-z showed that patients taking nucleoside reverse transcriptase inhibitors, drugs used to treat HIV for more than 30 years, reduced their risk of developing type 2 diabetes by 33%, a highly statistically significant result.

INmune Bio, Inc., a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced that the Company will be hosting a Key Opinion Leader webinar on the topic of treatment resistant depression at 1:00p.m. ET on Tuesday, September 29, 2020.

Mymetics has started a Covid-19 vaccine development project based on Mymetics’ virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine.

ARDS program well-positioned for an expedited path to commercialization with RMAT and Fast Track designation

American CryoStem Corporation is a clinical stage biotechnology company, global licensor, and a pioneer in autologous cellular therapy processing.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that its intranasal SARS-CoV-2 vaccine prototype for COVID-19, using BC-PIV technology, successfully induced systemic serum IgG and mucosal IgA neutralizing antibodies against the S1 antigen of SARS-CoV-2 in mice.

Intelligent Surgical Unit Enables Augmented Intelligence on the Senhance System

First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen’s COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S

Eagle Pharmaceuticals, Inc. announced that its marketing partner, SymBio Pharmaceuticals Limited, has received regulatory approval for TREAKISYM ready-to-dilute liquid formulation from the Pharmaceuticals and Medical Devices Agency in Japan.